Related references
Note: Only part of the references are listed.Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer et al.
LANCET (2021)
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
S. Peters et al.
ANNALS OF ONCOLOGY (2021)
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
Kazutaka Hosoya et al.
BMC CANCER (2021)
FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
B.C. Cho et al.
Journal of Thoracic Oncology (2021)
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC
R. Herbst et al.
Journal of Thoracic Oncology (2021)
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
J. Gray et al.
Journal of Thoracic Oncology (2021)
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
Elizabeth Dudnik et al.
ONCOIMMUNOLOGY (2021)
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
Florian Guisier et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
Natasha B. Leighl et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sex-associated molecular differences for cancer immunotherapy
Youqiong Ye et al.
NATURE COMMUNICATIONS (2020)
Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy
Meilin Jiang et al.
FRONTIERS IN ONCOLOGY (2020)
Sex and Gender Influences on Cancer Immunotherapy Response
Azzurra Irelli et al.
BIOMEDICINES (2020)
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients
Mihaela Aldea et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
Giuseppe Luigi Banna et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Human gut microbiota/microbiome in health and diseases: a review
Eman Zakaria Gomaa
ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY (2020)
Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer
Morgan R. L. Lichtenstein et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
Maria Silvia Cona et al.
CANCERS (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
Fabio Conforti et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Urania Dafni et al.
LUNG CANCER (2019)
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis
Leyin Zhang et al.
BIOMED RESEARCH INTERNATIONAL (2019)
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Yixin Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity
Regina E. M. Baiden-Amissah et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab
Jingjing Liu et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2019)
Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis
Rui Cao et al.
CANCER MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis
Yan Wang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
LBA78IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
D Spigel et al.
ANNALS OF ONCOLOGY (2019)
LBA79Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
R S Herbst et al.
ANNALS OF ONCOLOGY (2019)
LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
L Paz-Ares et al.
ANNALS OF ONCOLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
Hiren Mandaliya et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer
Takayuki Shiroyama et al.
CANCER MEDICINE (2018)
Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer?
Berna Akinci Ozyurek et al.
CLINICAL RESPIRATORY JOURNAL (2018)
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme
Francesco Grossi et al.
EUROPEAN JOURNAL OF CANCER (2018)
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
Alessandro Russo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti et al.
LANCET ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Rawad Elias et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.
Elizabeth Jimenez Aguilar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Elizabeth Dudnik et al.
LUNG CANCER (2018)
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
Yixin Zhou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis
Jie-Hui Zhong et al.
ONCOTARGET (2017)
Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients.
Laura Mezquita et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reduced naive CD8+ T-cell priming efficacy in elderly adults
Olivia Briceno et al.
AGING CELL (2016)
Biomarkers associated with checkpoint inhibitors
G. Manson et al.
ANNALS OF ONCOLOGY (2016)
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
Tomohiro F. Nishijima et al.
CANCER TREATMENT REVIEWS (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis
Xiao-Bin Gu et al.
SCIENTIFIC REPORTS (2015)
Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
R. D. Harvey
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Share Paper
